The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience
Abstract
AIM: To describe our experience in treating vitreoretinal involvement of primary central nervous system lymphoma, by intravitreal injections of methotrexate (MTX). METHODS: Patients with suspected intraocular lymphoma underwent a diagnostic vitrectomy. Samples were sent for cytology, genetic evaluation and for interleukin level measurements. Treatment protocol included injection of 400 microg/0.1 ml MTX intravitreally twice weekly for 4 weeks, once weekly for 8 weeks, and then once monthly for 9 months, for a total of 25 injections. Data were collected from the patients' records and included, inter alia, response to intravitreal MTX measured by time to disappearance of vitreal cells and retinal infiltrates, changes in visual acuity, and clinical recurrence rate. RESULTS: In the past 10 years we have treated 44 eyes of 26 patients; seven patients had monocular involvement, and 19 binocular. Six patients were initially diagnosed as having a non-responsive uveitis, and 16 with either CNS or systemic lymphoma with later involvement of the eye. Four patients had systemic lymphoma; one of them was found to have CNS lymphoma after the ocular involvement. Three patients had T cell lymphoma, and the rest had B cell lymphoma. Clinical remission was reached after 6.4 (3.4) (2-16) injections of MTX (mean (SD) (range)), with 95% of the eyes needing 13 injections or less to be cleared of malignant cells. None of the patients had an intraocular recurrence. Among the side effects, the most common was corneal epitheliopathy, which usually appeared after the third injection and began to subside when the intervals between injections increased. CONCLUSIONS: Vitreoretinal involvement of lymphoma can be controlled effectively and without serious adverse reactions by intravitreal MTX injections. The treatment protocol described herein has resulted in no intraocular recurrence so far and has had bearable side effects. The accumulating clinical results bring us to propose the consideration of this protocol as a good first-line treatment option for intraocular lymphoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primary central nervous system lymphoma
Hochberg, F. H., & Miller, D. C. (1988) · Journal of neurosurgery · doi:10.3171/jns.1988.68.6.0835 · Cited by 821
Smith, J. (2002) · Ophthalmology · doi:10.1016/s0161-6420(02)01125-9 · Cited by 277
Intravitreal Methotrexate as an Adjunctive Treatment of Intraocular Lymphoma
Fishburne, B. C. (1997) · Archives of Ophthalmology · doi:10.1001/archopht.1997.01100160322009 · Cited by 217
Shen, D. F., Zhuang, Z., LeHoang, P., Böni, R., Zheng, S., Nussenblatt, R. B., & Chan, C.-C. (1998) · Ophthalmology · doi:10.1016/s0161-6420(98)99036-4 · Cited by 160
High-dose methotrexate for intraocular lymphoma.
Batchelor, T. T., Kolak, G., Ciordia, R., et al. (2003) · PubMed · Cited by 152
Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma
de Smet, M. D., Vancs, V. S., Köhler, D., Solomon, D., & Chan, C. (1999) · British Journal of Ophthalmology · doi:10.1136/bjo.83.4.448 · Cited by 130
Kitzmann, A. S., Pulido, J. S., Mohney, B. G., Baratz, K. H., Grube, T., Marler, R. J., Donaldson, M. J., O’Neill, B. P., Johnston, P. B., Johnson, K. M., et al. (2007) · Eye · doi:10.1038/sj.eye.6702804 · Cited by 121
Cited by
Chan, C.-C., Rubenstein, J. L., Coupland, S. E., Davis, J. L., Harbour, J. W., Johnston, P. B., Cassoux, N., Touitou, V., Smith, J. R., Batchelor, T. T., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0210 · Cited by 486
Understanding intraocular lymphomas
Coupland, S. E., & Damato, B. (2008) · Clinical & Experimental Ophthalmology · doi:10.1111/j.1442-9071.2008.01843.x · Cited by 313
EMT and EndMT: Emerging Roles in Age-Related Macular Degeneration
Shu, D. Y., Butcher, E., & Saint-Geniez, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124271 · Cited by 292
Complications of intravitreal injections
Sampat, K. M., & Garg, S. J. (2010) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e328338679a · Cited by 287
INTRAVITREAL INJECTION OF THERAPEUTIC AGENTS
PEYMAN, G. A., LAD, E. M., & MOSHFEGHI, D. M. (2009) · Retina · doi:10.1097/iae.0b013e3181a94f01 · Cited by 255
Metadata
- Authors
- Frenkel, S., Hendler, K., Siegal, T., Shalom, E., & Pe'er, J.
- Venue
- British Journal of Ophthalmology
- Publisher
- BMJ
- Published
- 2008-02-26
- Volume
- 92
- Issue
- 3
- Pages
- 383-388
- ISSN
- 0007-1161 (ISSN-L)
- OpenAlex
- W2004349871
- Cited by
- 271
- References
- 7
- FWCI
- 8.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.